scholarly journals Use of Canagliflozin in Kidney Transplant Recipients for the Treatment of Type 2 Diabetes: A Case Series

Diabetes Care ◽  
2017 ◽  
Vol 40 (7) ◽  
pp. e75-e76 ◽  
Author(s):  
Harindra Rajasekeran ◽  
S. Joseph Kim ◽  
Carl J. Cardella ◽  
Jeffrey Schiff ◽  
Mark Cattral ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Kidney Transplant ◽  
Case Series ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Clinical Variables and Outcomes of Kidney Transplant Recipients with Type 2 Diabetes and New-Onset Diabetes after Transplantation in a Predominantly Minority Urban Population

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 541-P
Author(s):  
SANDRA ALEKSIC ◽  
SARA ZAHEDPOUR ANARAKI ◽  
EFFIE TSOMOS ◽  
LAXMI UPADHYAY ◽  
EMILY JAPP ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Kidney Transplant ◽  
Urban Population ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Clinical Variables ◽  
Onset Diabetes ◽  
Predominantly Minority ◽  
New Onset

scholarly journals The Use of GLP1R Agonists for the Treatment of Type 2 Diabetes in Kidney Transplant Recipients

2020 ◽  
Vol 6 (2) ◽  
pp. e524 ◽  
Author(s):  
Aleksandra Kukla ◽  
Jennifer Hill ◽  
Massini Merzkani ◽  
Andrew Bentall ◽  
Elizabeth C. Lorenz ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Kidney Transplant ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

scholarly journals 530. COVID-19 in kidney transplant recipients: Single-center experience and case-control study

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S332-S332
Author(s):  
Anna Hardesty ◽  
Aakriti Pandita ◽  
Yiyun Shi ◽  
Kendra Vieira ◽  
Ralph Rogers ◽  
...  
Keyword(s):  
Kidney Transplant ◽  
Case Control Study ◽  
Clinical Course ◽  
Case Series ◽  
Case Fatality ◽  
Case Control ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients ◽  
Transplant Patients ◽  
Control Study

Abstract Background Organ transplant recipients (OTR) are considered high-risk for morbidity and mortality from COVID-19. Case-fatality rates (CFR) vary significantly in different case series, and some patients were still hospitalized at the time of analyses. To our knowledge, no case-control study of COVID-19 in OTR has been published to-date. Methods We captured kidney transplant recipients (KTR) diagnosed with COVID-19 between 3/1 and 5/18/2020. After exclusion of KTR on hemodialysis and off immunosuppression (IS), we compared the clinical course of COVID-19 between hospitalized KTR and non-transplant patients, matched by sex and age (controls). All patients were discharged from the hospital or died. Results 16 KTR had COVID-19. All 3 KTR off IS, who were excluded from further analyses, survived. Median age was 54 (range: 34–65) years; 5/13 KTR (38.4%) were men. Median time from transplant was 41 (range: 1–203) months. Two KTR, both transplanted >10 years ago, were managed as outpatients. IS was reduced in 12/13 (92.3%), most often by discontinuation of the antimetabolite. IL6 levels were >1,000 (normal: < 5) pg/mL in 3 KTR. Tacrolimus or sirolimus levels were >10 ng/mL in 6/9 KTR (67%) (Table 1). Eleven KTR were hospitalized (84.6%) and matched with 44 controls. One KTR, the only one treated with hydroxychloroquine, died (CFR 5.8%; 7.6% in KTR on IS; 9% in hospitalized KTR on IS). Four controls died (CFR: 9%; state CFR: 5.2%; inpatient CFR: 16.6%). There were no significant differences in length of stay or worst oxygenation status between hospitalized KTR and controls. Four KTR (30.7%), received remdesivir, 4 convalescent plasma, 3 (23%) tocilizumab. KTR received more often broad-spectrum antibiotics, convalescent plasma or tocilizumab, compared to controls (Table 2). Table 1 Table 2 Conclusion Unlike early reports from the pandemic epicenters, the clinical course and outcomes of KTR with COVID-19 in our small case series were comparable to those of non-transplant patients. Calcineurin or mTOR inhibitor levels were high, likely due to diarrhea and COVID-19-related hepatic dysfunction. Extremely high IL6 levels were common. The role of IS and potential benefits from investigational treatments remain to be elucidated. A larger multi-institutional study is underway. Disclosures All Authors: No reported disclosures

scholarly journals Coronavirus disease 2019 infection in kidney transplant recipients: A clinical case series

2021 ◽  
Vol 32 (2) ◽  
pp. 579
Author(s):  
Arefeh Babazadeh ◽  
Masoumeh Asgharpour ◽  
ZeinabMohseni Afshar ◽  
Soheil Ebrahimpour ◽  
Sahar Oladzad
Keyword(s):  
Kidney Transplant ◽  
Clinical Case ◽  
Case Series ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients

Outcomes of Kidney Transplant Recipients with ESKD due to Plasma Cell Dyscrasia: A Case Series

2021 ◽  
Author(s):  
Alex R Dinh ◽  
Sandy W Wong ◽  
Thomas G Martin ◽  
Jeffrey L Wolf ◽  
Allison B Webber
Keyword(s):  
Kidney Transplant ◽  
Plasma Cell ◽  
Case Series ◽  
Plasma Cell Dyscrasia ◽  
Transplant Recipients ◽  
Kidney Transplant Recipients
Sign in / Sign up

Export Citation Format

Share Document